ReviewFrontiers in pharmacology2022
Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Multi-target synergistic mechanisms of flavonoid compounds from traditional Chinese medicine in non-alcoholic fatty liver disease: insights for human and veterinary medicine.Frontiers in veterinary science · 2026Pooled it
- Pharmacological effects of dihydromyricetin in preclinical models of NAFLD: a systematic review and meta-analysis stratified by dose and duration.Frontiers in pharmacology · 2026Pooled it
- Fruit and vegetable intake and the risk of non-alcoholic fatty liver disease: a meta-analysis of observational studies.Frontiers in nutrition · 2024Pooled it
- Exploring the Therapeutic Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Research progress on the roles and mechanisms of flavonoid monomers in liver diseases: a review.Molecular biology reports · 2026Review
- Redox Reprogramming of the Diseased Liver by Dietary Flavonoids: From Molecular Signalling to Gut-Liver Crosstalk.Biology · 2026Review
- Study on the Effect of Koumiss Extract in Alleviating Non-Alcoholic Fatty Liver Disease in Zebrafish Model by Improving Mitochondrial Function and Inhibiting Fat Deposition.Food science & nutrition · 2026Article
- Flavonoids in MASLD: preclinical mechanisms, pharmacological targets, and translational challenges.Frontiers in pharmacology · 2026Review
- The current consensus on ulcerative colitis, and the evidence and perspectives on the influence of gut microbiota on it.Frontiers in medicine · 2026Review
- Impact of Sarcopenia and Serum Creatinine on Clinical Outcomes after Tace in Hepatocellular Carcinoma.Journal of Cancer · 2026Article
- Using Machine Learning for the Discovery and Development of Multitarget Flavonoid-Based Functional Products in MASLD.Molecules (Basel, Switzerland) · 2025Article
- Cinnamic Acid: A Shield Against High-Fat-Diet-Induced Liver Injury-Exploring Nrf2's Protective Mechanisms.International journal of molecular sciences · 2025Article
- Flavone C-Glycosides fromNutrients · 2025Article
- Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD).Journal of molecular histology · 2025Review
- In vitro antioxidant effects and in vivo hepatoprotective effects of Osbeckia octandra, Vernonia cinerea and Atalantia ceylanica on a high fat diet induced metabolic dysfunction-associated steatotic liver disease mouse model.BMC complementary medicine and therapies · 2025Article
- Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats.Molecules (Basel, Switzerland) · 2025Article
- Possible protective effect of natural flavanone naringenin-reduced graphene oxide nanosheets on nonalcoholic fatty liver disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update.Nutrients · 2025Review
- The Effect of Flavonoids and Topiramate on Glucose Carbon Metabolism in a HepG2 Steatosis Cell Culture Model: A Stable Isotope Study.Nutrients · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide; however, there are currently limited treatments for NAFLD. The disease spectrum includes simple fatty liver, non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and progression to hepatocellular carcinoma (NASH-HCC). The therapeutic effects of NAFLD remain controversial. Although researchers have conducted studies on the pathogenesis of NAFLD, its pathogenesis and anti-NAFLD mechanisms have not been fully elucidated. Previous studies have found that flavonoids, as natural substances with extensive pharmacological activity and good therapeutic effects, have excellent antioxidant, anti-inflammatory, metabolic disease improvement, anti-tumor, and other properties and can significantly alleviate NAFLD. Flavonoids could be further developed as therapeutic drugs for NAFLD. In this paper, the pathogenesis of NAFLD and the mechanisms of flavonoids against NAFLD are summarized to provide a theoretical basis for screening flavonoids against non-alcoholic liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.